Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors.

Trial Details

NCT ID
NCT05784688
Phase
PHASE1 / PHASE2
Sponsor
TiumBio Co., Ltd.
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • TU2218 + KEYTRUDA® (Pembrolizumab)
Locations (sample)
  • San Antonio, Texas, United States|29.42412,-98.49363
  • Tyler, Texas, United States|32.35126,-95.30106
  • Spokane, Washington, United States|47.65966,-117.42908
  • Seongnam, South Korea|36.4052,127.7548
  • Seongnam, South Korea|36.4052,127.7548

Key Eligibility Criteria

  • Male and females ≥18 years of age
  • Life expectancy ≥12 weeks as judged by the Investigator
  • Measurable disease as defined by RECIST v1.1
  • ECOG 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →